Efforts to repeal the medical device tax aren't in vain, but they aren't going to be successful in bringing down the levy, Abbot Medical Optics president and former AdvaMed board chairman James Mazzo says.
*Correction Dec. 13, 2012: Mazzo is a member of AdvaMed's board of directors and he is chairman of the nominating committee.

Forget "cautious optimism" - the 2.3% medical device tax isn't going anywhere, according to Abbot Medical Optics president and former AdvaMed board chairman James Mazzo.
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...